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INTRODUCTION 
Diabetes mellitus is a health problem of first order as evidenced by the high 
prevalence and numerous consequences.1 Approximately 8.3% of the world population 
suffers from the disease with a similar proportion of undiagnosed patients. Further the 
incidence increases with age reaching to 11% in above- 65age group. It is the fourth 
common cause of death all over world as a direct cause not taking into account the 
cardiovascular mortality due to Diabetes2.  
 Diabetic foot infections are frequently occurring, complicated and costly 
problems in the lifetime of a diabetic.3 It ranks first among the most common diabetes 
related cause of lower limb amputation making upto 20% of all hospital admissions and 
prolonged hospital stay. Approximately 20% of the diabetic patients develop foot 
problems in the course of their lifetime and illness.  To add further to the burden about 
40% of them come back for readmission.4 
 Diabetic foot ulcers constitute the most common neurotraumatic cause of 
amputation5,6 as about 50% of the patients require a minor or major amputation.7 There is 
15 to 40 fold increased risk of requiring amputation than non-diabetics.  Diabetic foot 
infection increases the need for surgical management like amputation at various levels by 
50% when compared to uninfected Diabetic foot ulcers1.  
 The mortality rate reported in developed countries in diabetic foot infections is 
one among six of the diagnosed patients within one year of diagnosis.8 The burden is 
obviously under-reported in developing countries due to practical, social and economical 
grounds. 
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 Survival after amputation is significantly worse than the nondiabetic counterpart 
of the population, 3- year survival being 50% and 5-year survival being 40 %.9,10  And 
the prognosis is worse depending on the level of amputation; higher the level worse the 
prognosis10.  
The major predisposing factor for diabetic foot infections is presence of 
ulceration which is often a consequence of disease related  neuropathy, vascular disease 
and compromised immunity11,12.  
DFI has become one of the major medical, social and economical problem all 
over the world due to its implications on health and hence human resource. It becomes 
essential to have a detailed clinical study pertaining to the local burden and pattern of the 
disease. Enumeration of data from such studies in our locality will serve as pillars to 
support the implementation of modern multidisciplinary approach in management of 
DFI.  
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AIM AND OBJECTIVES 
 
AIM 
Emphasis the importance of integrated approach towards the diabetic foot 
management through study of microbiological data in tertiary care hospital. 
 
OBJECTIVES 
• To identify and isolate the common organisms causing infection in diabetic foot 
ulcers. 
• To study the Antimicrobial sensitivity pattern of the isolates 
• To study the prevalence of Multidrug resistant organisms in the isolates. 
• To identify the occurrence of  Polymicrobial infection in Diabetic foot infection. 
• To observe the risk factors for Polymicrobial infection in Diabetic foot infection. 
• To suggest an effective, economical Antimicrobial policy for treatment of 
Diabetic foot infection. 
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HISTORICAL REVIEW 
 
“Diabetes is a wonderful affection, not very frequent among men, being a 
melting down of the flesh and limbs into urine…. The patients never stop making 
water, but the flow is incessant, as if from the opening of aqueducts. The nature of the 
disease, then, is chronic, and it takes a long period to form, but the patient is short-
lived, if the constitution of the disease be completely established; for the melting is 
rapid, the death speedy.”   -- ARETAES.  
 It is understood from the history that the term possibly coined by Apollonius 
from Memphis  in 250BC , the ancient Greek word meaning “flow through” as the 
diseased lost more fluid compared to what they could drink. Mellitus is a Latin 
terminology meaning sweetened or honey like was added latter giving the phrase 
“diabetes mellitus”.  
 The Indian physician Sushruta in 400 B.C. described the sweet taste of 
urine from affected individuals, and for many centuries to come, the sweet taste of urine 
was the key to diagnosis. 
The earliest description of Diabetes mellitus could be seen in the Hindu writings 
since 1500 BC. It is described as “a mysterious disease causing thirst, enormous urine 
output, and wasting away of the body with flies and ants attracted to the urine of 
people.”  
15 
 
Ancient Egyptian history informs about the artificial foot made by them to 
facilitate the amputated people to walk and the process is well documented in their 
history. 13 
 
DEFINITION 
 WHO definition for Diabetic Foot is that “ The foot of a patient with 
diabetes that has the potential risk of developing pathological consequences like 
infection, ulceration/ destruction of deep tissue often associated with neurologic 
consequences, various degrees of vascular disease and or metabolic 
complications of diabetes”.  
 Boulton in 2002 simply defined Diabetic foot as “Any foot pathology that 
results directly from diabetes or its long term complications”14  
Any inframalleolar infection in a patient with Diabetes Mellitus which  presents 
as Paronychia, Cellulitis, Myositis, Abcess, Necrotizing fasciitis, Septic arthritis, 
Tendonitis or Osteomyelitis  is simply defined as DIABETIC FOOT INFECTION.15,16 
RISK FACTORS FOR DIABETIC FOOT INFECTIONS 17 
Risk factors for Diabetic foot ulcer are clearly defined in current literature 
nevertheless the body of evidence are not as great for risk factors of Diabetic foot 
infection.  
Significant independent risk factors for Diabetic foot infection includes                         
 1. Peripheral neuropathy  - Motor, Sensory and Autonomic  
2. Vascular (arterial) insufficiency  
3. Abnormal anatomy and biomechanics 
4. Hyperglycemia and other metabolic derangements  
5. Impaired neutrophil function 
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6. Impaired wound healing and excess collagen cross-linking 
7. Disease related disabilities 
8. Maladaptive behaviour from the patient side 
9. Inadequate healthcare provision  
PATHOPHYSIOLOGY OF DIABETIC FOOT INFECTIONS 7 
  Although DF lesions may seem different, the path leading to a foot ulcer and its 
complications is very similar, and is determined by various factors. Understanding of the 
pathophysiology of Diabetic Foot is essential for optimal care, since modifying the 
factors that influence its development can restore or keep the foot intact, conserving the 
limb and maintaining a healthy foot so that the patient can lead a completely normal life. 
The predisposing factors for diabetic foot infections are namely neuropathy, 
vasculopathy and immunopathy. 
The most common form of neuropathy is metabolic polyneuropathy, a condition 
characterized by symmetrical, distal, chronic, insidious onset, somatic and autonomic 
dysfunction. It predominantly affects the lower extremities14. It is found in 
approximately 30% of diabetics18, and increases in prevalence with increasing duration 
of disease19. 
          Peripheral neuropathy is an early factor in the pathogenesis & progression of 
diabetic foot manifestation and is considered the most prominent risk factor in 
development of foot ulcers in diabetics20. It leads to impaired perception and 
altered response to pain making the patient prone to injuries. Further, by altering 
gait biomechanics, developing hyperkeratosis (callosities) where plantar pressure is 
concentrated and ending up in ulcer due to extrinsic factors like improper 
footwear21.  
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        Motor component of peripheral neuropathy causes intrinsic muscle weakness 
and hence imbalance leading to deformities such as clawed digits. The resulting 
metatarsophalangeal joint instability leads to elevation in plantar pressure. 
Improper weight distribution marks the beginning of diabetic foot ulcers. 
          Autonomic dysfunction leads to changes in microcirculation resulting in 
arteriolar-venous shunting thereby diminishing effective perfusion and elevation of 
skin temperatures. Concomitant impairment of sebaceous and sweat gland makes 
the skin dry and thick that cracks and breaks more easily, becoming vulnerable to 
infection. 22,23 
 Sensory neuropathy in the foot and ankle clinic is diagnosed most 
commonly by testing protective sensation and loss of vibratory sensation12. 
Semmes-Weinstein (10-g) monofilament is used for protective sensation 
assessment and 128 Hz tuning fork for vibratory sensation.24 
           Diffuse multisegmental macro-angiopathy involving the infrapopliteal 
vessels, associated with compromised collateral circulation in Diabetic patients is 
the vascular abnormality in cases of foot pathology. It is similar to atherosclerosis 
of large vessels in other parts of the body. This presents as arterial insufficiency of 
the lower extremities compromising normal 
circulation.25  
Thickening of the basement membrane 
in capillary bed referred to as diabetic 
microangiopathy results in altered nutrient exchange and impaired oxygen 
transport.26 
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 The frequently observed inherent susceptibility to infection in the diabetic 
patient is attributed to Immunopathy. It has been implicated as the reason for 
impaired potential to mount a normal inflammatory response to infection and other 
immunological insults. The molecular pathology behind immunopathy is impaired 
leukocyte function and altered morphology of macrophages secondary to 
hyperglycemia.27 
               Leukocyte chemotaxis and phagocytosis is significantly reduced in 
diabetics and achievement of glycemic control results in improvement of 
microbiocidal rates. 
Impaired chemotaxis of cytokines and excess metalloproteinases create a 
prolonged inflammatory state that impedes normal wound healing.  
A catabolic state is established by  
1. Fasting hyperglycemia   
2. Presence of an open wound   
3. Insulin deprivation and 
4. Neoglucogenesis from protein sources.  
This metabolic alteration impairs protein synthesis, fibroblast proliferation 
and collagen deposit. Concurrent systemic deficiency of nutrients manifest  as 
delayed wound healing28.  
Field studies show impairment of the immune function with high blood 
glucose levels (≥150 ml/dl) 29.Diabetics do not fight infection effectively and 
infection adversely affects glycemic status. This vicious cycle worsens both the 
underlying disease and the incident complication 
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FLOW CHART DEPICTING PATHOPHYSIOLOGY OF DFI 
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EPIDEMIOLOGY 
 According to an estimate done in 2011 approximately 8.3% of the world 
population (366 million) suffers from Diabetes making it one of the highly 
prevalent diseases on earth. A similar proportion of undiagnosed patients have the 
disease, showing only the tip of the iceberg30. Among this around 80% of the 
population is in developing countries. In addition, there is an increase in incidence 
of the disease with age, reaching 11% in the persons over 65.31 The global burden 
is expected to hike to 9.9% of the adult population i.e. over 552 million in another 
one or two decade’s time.  Even in developed countries, it is the 4th cause of death 
as a direct cause, without taking into account its role in cardiovascular mortality, 
the leading cause of early death in diabetics.31,32,33. 
   India hosts the majority of diabetic subjects living all over the world. Presently 
33 million Indians are victims of diabetes and these scores are likely to reach 57.2 
million in another decade. This will account to one sixth of the world diabetes burden. 
Our country has already become the diabetes capital of the world. 
The annual limb loss due to Diabetes is more than 1 million. This means, 
every 30 second a diabetic person loses a lower limb at some part of the world. 
Due to effective treatment protocols diabetic patients having extended life 
expectancy, report with many problems, including diabetic foot. The main late 
complications of diabetes like atherosclerosis, neuropathy, retinopathy, etc. are 
vascular and metabolic in their pathogenesis.  
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The estimated burden of diabetes mellitus in the United States is more than 25 
million and 15-25% of them suffer from foot pathology like diabetic ulcer during their 
lifetime.34,35 More than 50% of the ulcers get infected, accounting for high rates of 
hospitalization, enhanced morbidity and consequent lower extremity amputation.  
Diabetic foot infections are the most common diabetes oriented etiology of 
hospital admissions accounting for 20% of all hospitalizations.36 Nearly 40% of the 
discharged patients come for readmission and approximately every one in six patient die 
within 1 year of development of infectious complication.37 The decision towards 
performing amputation is 50% more frequent when compared to diabetic ulcers without 
infection.38 
Foot ulcer is one of the most common complications in the lower 
extremities of diabetics. About 15% of patients experience DFU during the course 
of disease.39,40,41 Foot infections affecting the skin, soft tissues and bone with or 
without systemic impact are the most common reason for hospitalization of 
diabetics accounting to 25%; with prolonged periods of hospital stay.40 
Diabetes ranks first as the most common cause of lower extremity 
amputation in Europe and the U.S.42 The annual rate of amputations adjusted for 
age is 82 per 10,000 diabetics. The estimated risk of amputation in diabetics is 15 
to 40-fold greater than the nondiabetic counterparts. Men have at least 50% more 
risk than women .32,43  
The percentage of diabetics presenting with foot ulcer requiring amputation 
is 14-20% of total cases. Foot ulcer is the precursor of more than 85% of lower 
extremity amputations in these patients .44,45 Post- amputation incidence of a new 
ulcer, and/or contralateral amputation at 2-5 years is 50%.40,46 
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Survival of diabetic patients undergoing amputations is significantly worse 
than the rest of the population and even less if they have experienced another prior 
amputation.40 Only 50% to 40% of patients survive 3 and 5 years from an 
amputation, respectively, and prognosis worsens as the level where it is performed 
increases.46,47 
EVALUATION OF THE DIABETIC FOOT INFECTIONS48 
Evaluation of the infection in a diabetic wound is done at three levels, 
 General condition of the patient 
 Local condition of the limb 
 Local condition of the wound per se. 
 The aim is to assess  
 severity of the infection   
 cause of the infection 
 the  pathogenesis of the ulcer 
 altered anatomy and biomechanics  
 vascular disease  
 systemic manifestation of infection 
 Diagnosis of diabetic foot infection begins with clinical suspicion 
following a comprehensive elicitation of history and thorough physical 
examination, supported by complete laboratory evaluation, microbiological 
assessment and diagnostic imaging procedures.  
Diagnosis, correlation and management of diabetic foot infection can be 
challenging and should utilize the expertise of a multidisciplinary team comprising 
of surgeons, microbiologists, Diabetology physicians and paramedics. 
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Initial evaluation of the patient:  
          1. Basic metabolic panel 
2.  Complete Hemogram  
3. Urine routine examination  
4. Blood culture  
5. HbA1C 
6. C-reactive protein  
7. Serum albumin   
Evaluation of the Limb:   
1. Biomechanics                            Deformities ( Charcot arthropathy, 
                                                         Claw/hammer toes) ,callosities 
    
    
                                                                               
Clinical examination & Roentgenogram (≥2 images) 
2. Vascular status       
Arterial part                                            Ischemia/ necrosis/ gangrene 
 
 
Foot pulses, ABI, TcpO2, duplex USG 
&angiogram 
Venous                                           Edema/ stasis/ thrombosis  
 
Skin & soft-tissue examination and duplex USG   
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3. Neuropathy                 Loss of protective sensation     
         
Light touch/ monofilament pressure/ vibration perception 
 
 
 
 
EVALUATION OF THE WOUND:   
In spite of the fact that there are several classifications being proposed and 
implemented for the assessment of Diabetic foot ulcers / infections none is 
universally accepted. The classification schemes incorporate important parameters 
such as  
1. Depth and size of wound 
2. Ischemia  
3. Peripheral neuropathy  
4. Extent of infection. 
The following systems of classification are in vogue with their own 
advantages and limitations. 
1. Wagner’s classification 
2. UT classification  
3. The IDSA classification scheme 
 
 
27 
 
 
TABLE 1: Wagner Classification System 49 
 
GRADE DESCRIPTION OF ULCER 
0 Preulcerative area without open lesion 
1 Superficial ulcer (Skin thick) 
2 Deep ulcer involving tendon/capsule/bone 
3 Stage 2 +Abcess,Osteomyelitis,joint sepsis 
4 Gangrene of the wound 
5 Gangrene involving entire foot 
 
TABLE 2:     IDSA Classification of Severity of Diabetic Foot 
Infection50 
IWGDF 
PEDIS Grade 
IDSA   
Severity of 
Infection 
Clinical Signs of Infection 
GRADE 1 
 
NO INFECTION 
No inflammatory signs and effusion 
GRADE 2 
 
 
MILD 
INFECTION 
No systemic signs of infection. 
Evidence of purulence / 2 or more 
signs of inflammation 
GRADE 3 
 
 
 
MODERATE 
INFECTION 
No systemic signs of infection. 
Cellulitis >2cm. Deep tissue infection 
(crosses subcutaneous cellular tissue, 
no abscess, lymphangitis, arthritis, 
osteomyelitis, myositis or critical 
ischemia) 
GRADE 4 SEVERE INFECTION 
Any infection associated with 
systemic toxicity 
(fever,chills,vomiting,confusion,metab
olic instability,shock) 
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TABLE 3: University of Texas Health Science Center San Antonio 
classification system 51 
 
One of the most widely used Wagner’s classification does not take in to account 
the importance of ischemia and infection as independent risk factors in the classification 
Grades.   
 
The IDSA classification system consists of four level of infection that can be 
correlated to clinical findings. Even though it is widely accepted classification system it 
does not provide the complete description of local wound environment. (15) 
 
A recent classification of Diabetic foot ulcer called The University of Texas 
Health Science Centre San Antonio (UT) incorporates a matrix structure of four grades 
of wound depth with subgroups to denote the presence of infection, ischemia or both.  
 
 
 
 0 1 2 3 
A No open lesion Superficial 
wound Tendon/capsule Bone/Joint 
B With infection 
With 
infection With infection 
With 
infection 
 
C Ischemic Ischemic Ischemic Ischemic 
D Infection /Ischemia 
Infection / 
Ischemia 
Infection / 
Ischemia 
Infection / 
Ischemia 
29 
 
This limitation of IDSA classification system can be surpassed by integration of 
same with the UT classification for the better understanding of level of ulceration and the 
existence of ischemia. 
Absence of fever does not rule out infection in diabetic patients that may manifest 
as systemic signs like decreased blood pressure, increased pulse rate, and or severe 
hyperglycemia.  To make the diagnosis even more difficult, more than fifty percent of 
limp threatening infections do not manifest these systemic signs or symptoms. 52 
The importance of Local examination cannot be underestimated as the tunneling 
ulcers denote rapidly spreading deep seated infections that do not respect the anatomical 
planes. 53,54 
Pain and palpation of an otherwise insensate diabetic foot heralds more 
deep seated infections. As the violation of anatomical barriers is the routine 
occurrence in diabetic foot ulceration, assessment of dept of ulcer is crucial. 
In ulcers showing positive probe to bone examination, the positive 
predictive value for osteomyelitis is around 95 %.55,56 
Studies undertaken by abbot et al, Pecoraro et al and the American diabetes 
association consensus development of on diabetic foot wound have shown a lower 
positive predictive value of the test. But they came out with 91 percent negative 
predictive value. 
Considering all these study outcome a negative probe to bone test does not 
rule out a positive correlation with underlying osteomyelitis. 57 
Microbiological Evaluation 
A diabetic foot ulcer is considered to be infected when there is purulent 
discharge, or in the absence of it, the presence of erythema/ heat/ pain/ induration/ 
tenderness. 
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DFI almost invariably occurs in patients who suffer an ulcer in their life time59. A 
major cause of infections, often severe, of the lower limb is over infection by gram-
positive cocci from skin fissures in the interdigital spaces17.The diagnosis of the cause of 
the ulcer is essential in order to plan treatment and enhance healing of the ulcer. 
The simple presence of bacteria or any other pathogen is called contamination. 
However the ulcerative bed, rich in protein and other nutritive substances, constitutes a 
good broth for the microorganisms to reproduce in, leading to the phenomenon of 
colonization.  
The following step after colonization is infection. It is the tissue invasion of the 
microorganisms that triggers an inflammatory response with the appearance of the 
classical local signs and purulent secretion with or without systemic manifestations60.  
The bacterial burden appears to be involved in the transition from colonization to 
infection. There may be a critical point (105 cfu/g of tissue), influenced by the type of 
microorganism and immune status of the host at which the change from colonization to 
infection will take place. This is the so-called critical colonization61. 
 
The clinical significance of bacterial colonization lies in the circumstances of 
chronic nonhealing ulcers despite the absence of overt infection.62 This is clinically 
identified as  the presence of friable granulation tissue and a serous type secretion.63 The 
performance of quantitative cultures  may be indicated, with the purpose of detecting that 
critical colonization which would explain the inadequate course.64 
 This novel microbiological concept of critical colonization has changed the 
prescription of antimicrobial treatment of chronic ulcers with delayed healing not 
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explainable by other causes, provided that the quantitative cultures are significant, even 
at cost of overtreating some patients. 
One has to justify the clinical significance of the bacteria isolated as it is clear for 
highly virulent microorganisms, such as Streptococcus pyogenes, but not for most other 
recovered species that are usually opportunistic or commensal pathogens.65 
To address this issue, various solutions like quantitative and semi quantitative 
methods have been proposed with their own practical, clinical, social and economic 
limitations.66,67,68.  It is necessary to have microbiological criteria to assess the qualitative 
results received by the microbiologists. 
The microbial isolates of Diabetic foot infection depend on the type of infection 
and specific patient situations like antibiotic therapy, previous manipulation or 
hospitalization.69,70 
The aerobic gram positive bacteria especially staphylococcus aureus and beta-
hemolytic streptococci are the commonest organisms isolated from the previously 
untreated diabetic foot infection71 
Patient who underwent treatment with antimicrobials and or with deep seated 
ulcers are infected by polymicrobial pathogens. 71 
Anaerobic organisms are isolated from patients with mixed infections associated 
with gangrene72.   
Isolation of MRSA is more frequent in patients who underwent treatment in 
hospitals and or who were treated with broad spectrum antimicrobials. Recently the 
incidence of MRSA is found to be increasing even in the absence of above said 
conditions due to the increased prevalence of community acquired MRSA infection.73,74 
MRSA is anticipated in:  
 1) h/o earlier colonization or previous infection MRSA  
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2) prevalence of MRSA infection at the locality over10%. 
 3) if  ≥2 of the following conditions are present, 
a) h/o hospitalization in the past year or patient is from a healthcare center 
with endemic MRSA disease 
b) treatment with a fluoroquinolone in the previous 6 months  
c) > 65 years of age                                                                                                                           
 d) h/o dialysis program for nephropathy.75  
 
ESBL- producing E. coli is looked for in 
a.> 65 years,  
b. female gender  
c. hospitalization in the previous year, 
d. recurrent urinary tract infection,  
e. prior use of fluoroquinolones. 
f. Diabetes per se.76  
Enterococcus spp, CNS, P. aeruginosa, are expected in cases of chronic humid 
and macerated ulcers receiving multiple treatments.77  
 
 
Common expected pathogens such as S aureus, À-hemolytic streptococci, 
enterobacteria or anaerobes should be given importance at the point of isolation. Other 
isolates are considered when they are found in a pure culture or on repeated isolation. No 
species should be disregarded given the polymicrobial nature of the biofilm of chronic 
diabetic foot ulcers that warrants attention and repeat cultures in case of an unfavorable 
course.78.79,80  
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TABLE 4: Infectious Profile of DFI 
INFECTION MICROORGANISMS 
Cellulitis Staphylococcus aureus  
Erysipelas  Streptococci  
Ulcer untreated with antibiotics Staphylococcus aureus, Streptococci 
Ulcer treated with antibiotic or 
on long term therapy  
MRSA, MSSA, CONS, Streptococci, Enterococci, 
Enterobacteriaceae, Pseudomonas aeruginosa ,Other 
nonfermentors, Corynebacterium spp.Candida spp. 
Necrotizing fasciitis of 
myonecrosis(generally 
polymicrobial) 
Anaerobic gram positive cocci 
Enterobacteriaceae,Non fermenting gram negative 
bacilli, anaerobes 
 
ANTIBIOTICS in DIABETIC FOOT INFECTION 
It has continued to be a controversial issue relating to the institution of empirical 
antibiotic therapy for Diabetic foot infections. Even positive evidence from microbiology 
department does not always justify the extensive use of antibiotics. 81 
Clinical criteria suggesting local or systemic infection are taken as supporting 
factor for such decision. Situations like Osteomyelitis are exceptions when the laboratory 
data is given weightage.82. 
The Factors to be taken into consideration while planning for an antibiotic 
regimen are, 
1. Efficiecy of the vascular system for effective bioavailability of the drug 
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2. Immunological Competency of the patient 
3. Renal function   83 
 Vascular insufficiency and immunological incompetency warrant prolonged 
periods of administration of bactericidal antibiotics.  Anticipation of Renal failure in 
chronic diabetics leads to avoidance of nephrotoxic drugs, such as aminoglycosides, 
Vancomycin and amphotericin B 84,85   
The constitution of empirical antimicrobial battery of drugs is based upon the 
severity of infection, the duration of lesion, previous treatment with antibiotics and local 
sensitivity pattern. 
Gram positive cocci being the predominant pathogens in any circumstance as 
supported by various global and national studies should always be covered.  
RECOMMENDED PROTOCOL 
For mild and mild to moderate infections stratified according to the classification 
systems discussed earlier oral amoxicillin Clavulanic acid is recommended  as first line 
drugs for a period of 7 – 14 days. 69,75  
When MRSA / CONS is suspected the above supplemented with cotrimoxazole 
or Linezolid.  
In beta lactum allergic patients the alternatives are Levofloxacin / Moxifloxacin/ 
Clindamycin/ cotrimoxazole. 
Moderate-severe  infections  require intravenous administration and hence 
hospitalization. Antibiotics effective to combat  
35 
 
Staphylococcus spp and Streptococcus spp 
Enterobacteriaceae 
Streptococcus spp,  
Peptostreptococcus spp and Bacteroides spp like  
 Ertapenem,a third-generation cephalosporin71 plus metronidazole 
or amoxicillin-clavulanate may be used140. piperacillintazobactam 
can be supplemented if there is suspicion about the involvement of Pseudomonas spp. 
In severe infections with systemic impact and lifethreatening 
all possibilities should be covered with betalactams with antipseudomonal activity 
(carbapenem or piperacillin-tazobactam) combined also with daptomycin, linezolid 
or vancomycin if there is a risk of MRSA.  
Monotherapy with beta-lactams at high doses, namely, a carbapenem, 
piperacillin-tazobactam or fourth-generation cephalosporin's165 or quinolones 
(particularly in patients allergic to penicillin) is as effective as combined treatment with 
aminoglycosides and safer, according to data from nonrandomized  clinical series  
Failure of a correct antibiotic treatment may be due to the development of 
resistance, overinfection or extension to bone.We should remember that hospitalized 
patients and those previously treated with broad-spectrum antibiotics over a long period 
usually have resistant bacteria. 
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TABLE 5: Treatment of DFI 
 Infection First choice  Alternative  
 
Mild  
 
Mild – moderate  
Oral amoxicillin – clavulanic 
acid  
 
 
Oral levofloxacin or moxifloxacin 
 
Oral clindamycin 
Oral cotrimoxazole 
Oral linezolid 
Moderate severe  IV ertapenem 
± 
IV daptomycin or IV linezolid 
 or IV glycopeptite 
 
IV amoxicillin – clavulanic acid 
 
IV 3rd generation cephalosporin+IV 
metronidazole 
 
Or 
IV fluoroquinolone2  + IV 
metronidazole 
Or  
IV piperacilln –tazobactam3 
Or 
IV imepenem or IV meropenem3 
 
± 
IV daptomycin or IV linezolid or 
IV glycopeptite1 
 
 
Severe   
IV imepenem or IV 
meropenem 
 
Or  
 
IV piperacilln –tazobactam 
 
IV daptomycin or IV linezolid 
or IV glycopeptite1  
IV tigecycline 
 
+ 
IV fluoroquinolone2 or IV 
amikacin 
 
1 Suspected MRSA   2 Ciprofloxacin or levofloxacin  3 Suspected P.aeruginosa 
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MATERIALS AND METHODS 
 
PLACE OF STUDY   : Thanjavur Medical College Hospital, Thanjavur. 
STUDY PERIOD   : One year between April 2011 and April 2012 
COLLABORATING DEPARTMENTS: Medicine, Surgery, and Diabetology.  
DESIGN OF STUDY  : Observational study 
ETHICAL CLEARANCE : Prior approval obtained from Ethical Committee 
INFORMED CONSENT : Obtained from each patient 
INCLUSION CRITERIA : Patients with H/O Type II Diabetes mellitus 
1. attending Diabetic clinic for DFI/DFU 
       2.admitted in Sugical wards for DFI/DFU 
        3. attending surgery OP for DFI/DFU 
The patients of all age groups belonging to both the sex with DFU/DFI with or without 
systemic signs and symptoms of infection were considered and included in the study. 
EXCLUSION CRITERIA: 
Those with Type I Diabetes mellitus and associated co-morbid conditions, immuno 
compromised patients, HIV Positive patients were excluded.  
SPECIMEN COLLECTION AND TRANSPORT 
 Specimens for microbiological assessment (frank pus, purulent discharge, 
serosanguinous discharge) were obtained at the time of admission & at the time of visit to 
OPD, after thorough vigorous saline wash followed by wound debridement of superficial 
slough and exudates. Specimens were collected by scraping the ulcer base or the deeper 
portion of the wound edge with sterile curette into a wide- mouhed sterile container or 
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scavenged using sterile swabs and transported to the microbiology lab without undue 
delay.85,86 
SPECIMEN PROCESSING 
MICROSCOPY 
Direct smears are made from the specimens; gram staining was done and 
examined under oil immersion for the presence of pus cells, epithelial cells, bacteria and 
fungi and to assess quality of the sample.  
      GNB IN DIRECT SMEAR                                        GPC IN DIRECT SMEAR  
 
CULTURE MEDIA USED 
     1. MacConkey agar 
     2. Blood agar 
 3. Nutrient agar  
 CULTURE METHOD:   
Mother inoculum was made with the specimen loaded swab or by loading sterile 
inoculation loop with the curetted material and Streak culture was done  using flame 
sterilized Nichrome loop. Plates were incubated overnight at 35 - 37°C in ambient air. 
Culture plates were examined the next day for growth and observations were recorded. The 
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isolated colonies were identified by adopting the procedures of Gram staining, motility and 
routine biochemical reactions.  
BIOCHEMICAL REACTIONS: 
 The following tests are routinely done on the isolates. 
1. Catalase Test                              
2. Oxidase Test  
3. IMViC Test  
4. Urease Test  
5. TSI      
6. LAO decarboxylation 
7. OF Test 
8. Sugar Fermentation Reactions 
 9.Bile esculin hydrolysis 
10. Coagulase Test 
IDENTIFICATION OF STAPHYLOCOCCUS AUREUS      
Golden yellow pigmentation                                    Yellow colonies on MSA              
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Staphyococcal isolates were identified  by the specific colony characters like golden 
yellow opaque colonies on NAP, β hemolysis on BAP and Coagulase test.  
COAGULASE TEST     β hemolysis in blood agar 
 
 
 
DENTIFICATION OF PSEUDOMONAS AERUGINOSA  
Green pigmentation on nutrient agar                         NLF colonies on MacConkey Agar 
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BIOCHEMICALS FOR P.AERUGINOSA 
 
 OF & LAO TEST                                                  OXIDASE TEST 
  
 
 
 
 
 
DENTIFICATION OF PROTEUS SPP. 
SWARMING ON BLOOD AGAR                      BIO CHEMICAL REACTIONS 
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DENTIFICATION OF KLEBSIELLA SPP. 
KLEBSIELLA SPP.ON MACCONKEY AGAR 
                  
 
 
 
 
 
 
 
BIO CHEMICAL REACTIONS 
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ENTEROBACTER SPP. ON MACCONKEY AGAR 
 
 
 
 
 
 
 
 
BIO CHEMICAL REACTIONS 
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ESCHERICHIA COLI ON MAC 
 
 
 
 
 
 
 
BIO CHEMICAL REACTIONS 
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ANTIMICROBIAL SENSITIVITY TESTING87 
The antimicrobial sensitivity pattern for all the isolates were done in Muller Hinton 
Agar by modified Kirby – Bauer disc diffusion method as per CLSI guidelines using 
antibiotic discs (Himedia, Mumbai). 
 
STORAGE OF ANTIMICROBIAL DISCS 
 All the antimicrobial discs are stored in refrigerator at 4 - 8° C except the β-lactum 
antibiotics that were stored in the freezer compartment until the day of use. 
 Discs are brought to room temperature before application. They are replaced in air-
tight containers after use. 
MCFARLAND TURBIDITY STANDARD 88 
  0.5 McFarland turbidity standard is prepared by adding 99.5ml of 1% sulphuric 
acid and 0.5 ml of 1.175 % barium chloride.  Standards ranging from 0.1 to 1.0 are 
prepared and dispensed in screw-capped test tubes comparable to those used for inoculum 
preparation, which are sealed tightly and stored in the dark at room temperature.  The 
bacterial suspension that matches with 0.5 McFarland standard provides an inoculum 
containing approximately 1.5 X 10 8 CFU/ml. 
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PREPARATION OF INOCULUM 
 In order to prepare the inoculum, about 3-5 representative colonies were picked up 
and inoculated in 4-5 ml of peptone water and incubated at 37°C for 2 – 6 hrs to attain 
turbidity equivalent to 0.5 McFarland’s standard which corresponds to 150 million 
organisms/ml.  Turbidity match is done against contrasting black and white background. 
INOCULATION OF MHA PLATES 
A sterile swab is dipped in the inoculum within 15 minutes of adjusting the 
turbidity of the inoculum and pressed firmly against the sidewall of the test tube to drain 
the excess broth. Muller Hinton agar plate is inoculated by streaking the swab over the 
entire sterile agar surface by streaking two more times and rotating the plates at an angle of 
approximately 60°c to ensure an even distribution of inoculum. The rim of the agar is 
swabbed by a circular motion. The closed plate is left for 3-5 minutes to allow any excess 
surface moisture to be absorbed before applying antimicrobial discs. 
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APPLICATION OF ANTIMICROBIAL DISCS 
 The battery of drugs to be applied is determined and the following antimicrobial 
discs - Gentamicin, Amikacin, Amoxycillin, 
Ampicillin, Amoxyclav, Oxacillin, 
Erythromycin, Cotrimaxazole, Doxycycline, 
Ciprofloxacin, Ofloxacin, Cephelexin, 
Cefixime,  Ceftazidime, Ceftriaxone, 
Cefotaxime, Cefipime, Ceftazidime-
Clavulanicacid, Aztreonam, Imipenam, and     
are tested for all the  isolates.  
Along with the above drugs Azithromycin and Vancomycin are tested for gram 
positive cocci. Piperacillin-Tazobactum was used only for E. coli, Klebsiella and 
Pseudomonas. The discs are placed on agar plates using thumb forceps and pressed down 
gently to ensure complete contact with the agar surface.  Discs are applied in such a 
manner that a minimum of 25 mm distance is ensured from centre to centre of the discs. 
The plates are then incubated at 37° C for 16 – 18 hrs in ambient air. 
Control strains are also inoculated following the same procedure. 
 
INTERPRETATION 
 After the stipulated period of incubation, the plates are examined under good light. 
Satisfactory streaking is confirmed by semiconfluent lawn of growth and uniform circular 
zones of inhibition.   
The zones of complete inhibition from the centre of the discs are measured. The 
zones are measured to the nearest millimeter using zone scale (Himedia).  The Petri plate is 
held a few inches above a black, non reflecting background illuminated with reflected 
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light.  Zone of inhibition is the margin showing no obvious visible growth detected with 
naked eyes and interpreted by referring to the CLSI standard guidelines updated from time 
to time. The organism is reported as sensitive or resistant to the drugs that are tested. An 
intermediate zone of inhibition is also reported but the clinical application of the data is 
doubtful. 
Control plates were also read using the same procedure and reliability of the test is 
ensured. 
 
CONTROL STRAINS USED WITH EACH BATCH  
 
    ATCC PSEUDOMONOS                                        
 
     
    Escherichia coli ATCC 25 
 
   Pseudomonas aeruginosa ATCC 27853 
 
Staphylococcus aureus ATCC 25923 
 
SCREENING FOR MRSA89 
 The screening for MRSA is done by 
Oxacillin screen agar method recommended by 
The National Committee for Clinical Laboratory 
Standards (NCCLS) containing 6 µg/ml of 
oxacillin or by disc diffusion on Müeller-Hinton 
agar supplemented with 4%NaCl .  
 Spot inoculum over 1-1.5 inch area or 
routine lawn culture method can be applied. In 
both methods, any growth after complete 24 hours 
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of incubation at 35°C in ambient air denotes oxacillin resistance, provided controls are 
satisfactory. 
 
SCREENING FOR ESBL PRODUCTION87 
Modified Kirby Bauer disc diffusion method 
                                                                        Isolates showing inhibition 
zones <22 mm for Ceftazidime, < 
27 mm for Cefotaxime, <25 mm 
for Ceftriaxone, <22 mm for 
Cefpodoxime and <27 mm for 
Aztreonam were identified as 
potential ESBL producers and 
they were tested further. 
 
 Double disc synergy test87 
To demonstrate a synergistic action between a 3rd generation Cephalosporin and 
Clavulanic acid, isolates were grown and adjusted to 0.5 McFarland’s standard and lawn 
culture of it was made on MHA plate. 
Discs of 3rd generation Cephalosporin, 
Cefotaxime (30µg) and Ceftazidime (30µg) were placed 
20 mm apart from an amoxicillin (20µg) and Clavulanic 
acid (10µg) combined disc from centre to centre and 
incubated at 37°C for 16 – 18 hrs. If inhibition zone 
around the 3rd generation Cephalosporins showed a clear extension towards Amoxycillin- 
Clavulanic acid disc then the organisms were said to be ESBL producing.   
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Phenotypic confirmation test 
Inhibitor potentiation disc 
diffusion test (NCCLS 
confirmatory test)53 
ESBL production was confirmed by 
Ceftazidime (30 µg) and Ceftazidime 
plus Clavulanic acid (30 /10 µg) 
placed on inoculated MHA plates and 
incubated.  Organism was considered as ESBL producer if there was ≥ 5mm increase in 
diameter of Ceftazidime/ Clavulanate disc than that of Ceftazidime disc alone.  
 
E-test for ESBL 90,91 
Combination of disc diffusion and 
Minimum Inhibitory Concentration (MIC) 
were studied using the E-test strips. The E-
test strip contains Ceftazidime gradient at 
one end and Ceftazidime plus Clavulanate 
gradient on the opposite end.  MHA were 
inoculated as for disc diffusion and the 
strips were placed on the inoculated lawn 
and incubated.  MIC was the point of intersection of the inhibition ellipse with the E-test 
strip edge.  Ratio of ceftazidime MIC and Ceftazidime Clavulanic acid MIC ≥ 8 indicated 
the presence of ESBL.  
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Quality Control (QC) used for ESBL production:   
E. coli A7CC 25922 - Negative control 
Klebsiella pnemoniae ATCC 700603 – Positive control 
 
Tests for Amp C β lactamase production 
 Disc Antagonism test92 
The organisms that exhibited 
resistance to 3rd generation 
cephalosporins and cefoxitins were 
swabbed onto a Muller - Hinton Agar 
Plate and  Cefoxitin (30  µg) and 
Ceftaxidime (30 µg) discs are placed at 
a distance of 20mm from centre to 
centre and incubated overnight at 37° C.   
Amp C β-lactamases inducibility was 
recognized by blunting of the Ceftazidime zone adjacent to Cefoxitin disc92,93. 
Amp C disc test (Black et al., 
2005)94 
The test is based on the use of 
Tris – EDTA to permeabilize bacterial 
cell and release β-lactamases into the 
external environment.  Amp C discs (i.e., 
filter paper disks containing Tris-EDTA) 
were prepared in house by applying 20 µl 
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of 1:1 mixture of saline and 100 X Tris – EDTA to sterile filter paper discs allowing the 
discs to dry and storing them at 2- 8 °C.  The surface of a MHA plate was inoculated 
with a lawn of Cefoxitin- susceptible E. coli ATCC 25922 according to the standard disc 
diffusion method.  Immediately prior to use, Amp C discs were rehydrated with 20 µl of 
saline and several colonies of each test organism were applied to a disc.   
A 30 µg Cefoxitin disc was placed on the inoculated surface of the MHA.  The 
inoculated Amp C disc was then placed almost touching the antibiotic disc with the 
inoculated disc face in contact with the Agar surface.  The plate was then inverted and 
incubated overnight at 35 °C in ambient air.  After incubation, plates were examined for 
either a distortion, indicating no significant inactivation of Cefoxitin (positive result), or 
the absence of a distortion, indicating no significant inactivation of Cefoxitin (negative 
result). 
LIMITATIONS OF THE STUDY :  
1.  Isolation of Anaerobes was not done. 
2. Genomic  study was not carried out. 
 
STATISTICS: Simple descriptive statistics was used to analyze the data. 
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TABLE 6: Zone Size Interpretation Chart According To CLSI87 
Sl. 
No. 
Antimicrobial 
agent 
Symbol Drug 
concentration (µg) 
Zone size in mm 
Resistant Intermediate Sensitive 
A. Aminoglycosides 
1. Gentamicin  G 10 < 12 13-14 > 15 
2. Amikacin  AK 30 <14 15-16 >17 
B. Penicillin 
1. Ampicillin  A 10 <13 14-16 >17 
C. Sulphonamides 
1. Cotrimoxazole CO 1.25/23.75 <10 11-15 >16 
D. Quinolones 
1. Nalidixic acid NA 30 <13 14-13 >19 
2. Norfloxacin NX 10 <12 13-16 >17 
3. Ciprofloxacin CF 5 <15 16-20 >21 
4. Levofloxacin LE 5 <13 14-16 >17 
E. Cephalosporins 
1. Cephelexin CP 30 <14 15-17 >18 
2. Cefuroxime CU 30 <14 15-17 >18 
3. Cefoxitin CN 30 <14 15-17 >18 
4. Ceftazidime CA 30 <14 15-17 >18 
5. Ceftriaxone CI 30 <13 14-20 >21 
6. Cefotaxime CE 30 <14 15-22 >23 
7. Cefpodoxime CEP 10 <17 18-20 >21 
8. Cefipime CPM 30 <14 15-17 >18 
F. Monobactams 
1. Aztreonam AO 30 <15 16-21 >22 
G. Carbapenems 
1. Imipenam  I 10 <13 14-15 >16 
H. β lactam - β lactamase inhibitor 
1 Amoxyclav AC 20/10 <13 14 – 17 >18 
2 Piperacillin-
Tazobactum 
PT 100/10 17 18 – 20 21 
3 Cefeperazone-
Sulbactum 
CFS 75 / 10 15  16 20 21 
I. Macrolides 
1. Azithromycin AT 15 <13 14-17 >18 
K. Glycopeptide 
1. Vancomycin V 30 <14 ---- >15 
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RESULTS 
 During the study period from April 2011 to April 2012, a total number of 142 
samples were collected from 142 patients with DFI/DFU attending SURGERY and 
DIABETOLOGY Out Patient Department and those admitted at Thanjavur Medical 
College Hospital, Thanjavur. The total 142 samples were processed in the Microbiology 
laboratory of Thanjavur Medical College and Hospital.  
 Among the total population, 85 males (59.85%) and 57 females (40.15%) were 
affected by Diabetic foot infection [Table 1]. The mean age of the subjects was Out of 
the 142 specimens processed, 119 (84%) showed significant growth and 23 (16%) 
yielded no growth of organisms.  
 The processed 119 samples yielded a total of 165 organisms, the polymicrobial 
isolation being the reason behind. 81(68%) samples yielded monomicrobial growth while 
38 samples (32%) showed polymicrobial growth. 
 The following organisms were isolated from the 142 samples subjected for study 
and the 119 positive cultures. Staphylococcus aureus - 31(26%), Pseudomonas spp. - 
28(24%), Proteus spp.- 25(21%), Enterococci -15(13%) Enterobacter-14(12%), 
Klebsiella spp. - 13(11%), Escherichia coli - 10(8%), CONS - 10(8%), Corynebacterium 
spp.-8(7%), Nonhemolytic Streptococci-5(4%), Acinetobacter-3 (2.5%) and Citrobacter - 
3(2.5%) [Table 4]. 
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TABLE 7: Distribution by Age & Gender 
 
DISTRIBUTION BY AGE & GENDER 
AGE 
RANGE 
MALE 
 
FEMALE TOTAL 
PERCENTAGE 
No. PERCENTAGE No. PERCENTAGE 
 30 – 39 10 12 7 12 17 12 
40-49 11 13 16 28 27 19 
50-59 20 24 11 19 31 22 
60-69 28 33 17 30 45 32 
70-79 12 14 6 11 18 13 
80-90 4 5 0 0 4 3 
 
 
CHART 1: Distribution by Age & Gender 
 
The prevalence of DFI was more in males than females. Majority of 
the study subjects fall in the 60 – 69 age group. 
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TABLE 8: Distribution by Disease Duration  
 
DISTRIBUTION BY DISEASE DURATION  
DURATION  
IN YEARS 
MALE 
 
FEMALE 
 TOTAL PERCENTAGE 
NO. PERCENTAGE NO. PERCENTAGE 
≤5 35 41 27 47 62 44 
6 TO 10 30 35 21 37 51 36 
11 T0 15 17 20 7 12 24 17 
16 TO 20 2 2 2 4 4 3 
≥20 1 1 0 0 1 1 
  85   57   142 100 
 
 
CHART 2: Distribution by Disease Duration 
 
 80% of the study subjects were suffering from diabetes for a period of about 10 
years. Greater the duration of illness higher the incidence of MDRO isolates. 
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TABLE 9: Incidence of Associated Complications 
ASSOCIATED COMPLICATIONS 
DISEASE NUMBER OF PATIENTS PERCENTAGE 
NEUROPATHY 125 88 
NEPHROPATHY 40 28 
PERIPHERAL 
VASCULAR DISEASE 127 90 
RETINOPATHY 29 20 
HYPERTENSION 43 30 
 
CHART 3: Incidence of Associated Complications 
 
 90% of the patients had Peripheral vascular disease and 88% of the study 
population had neuropathy as associated complication of the disease and as risk factor  
for development of ulcer. 
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TABLE 10: Distribution of Isolates 
S.NO NAME OF THE ISOLATE NO.ISOLATED PERCENTAGE 
 
1 STAHHYLOCOCCUS 31 26 
2 PSEUDOMONAS SP 28 24 
3 PROTEUS SP 25 21 
4 ENTEROCOCCUS SP 15 13 
5 ENTEROBACTER 14 12 
6 KLEBSIELLA 13 11 
7 CONS 10 8 
8 ESCHERICHIA COLI 10 8 
9 CORYNEBACTERIUM SP 8 7 
10 NH STREPTOCOCCUS 5 4 
11 CITROBACTER 3 3 
12 ACENETOBACTER 3 3 
    165   
 
CHART 4: Distribution of Isolates 
 
58% of isolates are Aerobic gram negative organisms and remaining 42% being aerobic 
gram positive bacteria.38 out of 119 patients showed polymicrobial growth. 
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Staphylococcus is the most frequent pathogen found in nearly 26% of infection. 
Enterococcus Spp. constitutes next frequent gram positive isolate. (13%). Majority of 
studies also noted high frequency of these microorganisms in foot infection of diabetic 
patients. (39, 41, 42) 
In this study gram negative bacteria were most frequently isolated, this finding is in 
concurrence with the several other Indian studies (40, 42,43) though  the same is in contrast 
with the foreign studies. The difference in age - sex composition, study setting, socio 
economic factors might be reason behind these differences. 
There was high recovery of pseudomonas isolates in these study subjects that showed 
multi drug resistance as well. This raises a serious concern as multi drug resistant isolates 
were more frequently found in hospitalized patients after considerable period of stay. 
The usage of broad spectrum antibiotics, prolonged usage of antibiotics could be the 
factors behind this observation. (42) 
TABLE 11: Correlation between Duration of Disease, Polymicrobial 
Isolates  and MDRO Occurrences 
 
INCIDENCE OF MDRO & POLYMICROBIAL 
 
Duration 
of 
Diabetes 
in years 
Total 
number of 
Patients 
Total 
number 
of 
MDRO 
MDRO   
Percentage 
Total number 
of 
Polymicrobial 
Polymicrobial   
Percentage 
1 4 3 75 0 0 
2 18 8 44 4 22 
3 15 7 47 4 27 
4 8 4 50 1 13 
5 17 8 47 10 59 
6 5 2 40 3 60 
7 6 5 83 3 50 
8 11 6 55 5 45 
9 1 1 100 1 100 
10 28 21 75 20 72 
11 1 1 100 1 100 
12 6 3 50 4 67 
13 2 2 100 2 100 
15 15 10 67 12 80 
17 1 1 100 1 100 
20 3 2 67 2 67 
22 1 1 100 1 100 
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CHART 5: Correlation between Duration of Disease and Polymicrobial 
Isolates 
 
 As the duration of the disease  increases the  frequency of  polymicrobial 
colonization and MDRO incidence is also more.This observation is explaind by the 
immunological compromise experienced by diabetics and prolonged periods of 
treatment.  This is supported by studies from northern India. (43)     
 The prolonged periods of hospital stay also increases the incidence of 
polymicrobial infection and development of multi drug resistance. This is in accordance 
with the other studies.(43,44)     
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CHART 6: Correlation between Duration of Disease and MDRO 
Isolates 
 
 
 
TABLE 12: Relationship between Prolonged Stay, MDRO & 
Polymicrobial Isolates 
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RELATIONSHIP BETWEEN DURATION OF STAY & INCIDENCE OF MDRO 
Stay in 
Weeks 
Total 
Number of 
Patients 
Total 
Number of    
MDRO 
MDRO 
Percentage 
Total number of 
Polymicrobial 
Polymicrobial 
Percentage 
1 5 3 60 0 0 
2 25 15 60 2 8 
3 30 7 23 5 17 
4 24 10 42 4 17 
5 10 6 60 4 40 
6 27 17 63 10 37 
7 1 1 100 1 100 
8 12 10 83 10 83 
12 5 5 100 5 100 
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CHART 8: Relationship between Prolonged Stay & Polymicrobial 
Isolates 
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TABLE 13: Correlation between Glycemic Control & Amputation 
Glycemic 
control Total 
MDRO 
Polymicrobial 
infection 
 
Amputation 
 
 
No. Percentage No. Percentage No. Percentage 
FBS≥110 98 55 56 25 26 87 
 
96 
PPBS≥160 142 71 50 29 30 91 
 
100 
 
Poor glycemic control in patients is identified as an independent risk factor for MDRO 
infection and in turn to amputation that is in accordance with  a study in AIIMS.(43) 
Amputation rates are higher when there is infection with multi drug resistant organism. 
Among the patients with MDRO infection 96% of them underwent amputation.62% of 
total amputations were performed on patients with MDRO infection. 
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TABLE 14: Clinical Outcome 
CONSERVATIVE AMPUTATION 
TOTAL PATIENTS  51 91 
 PERCENTAGE 36% 64% 
 
 
CHART 10: Clinical Outcome
 
 
 
TABLE15: Correlation between MDRO & Amputation 
 
AMPUTATION MDRO POLYMICROBIAL GROWTH 
NO.OF PATIENTS  
 
91 56 24 
 PERCENTAGE 
 
64% 62% 26.37% 
 
 
 
36%
64%
CLINICAL OUTCOME
CONSERVATIVE
AMPUTATION
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TABLE16:   AMS Pattern of STAPHYLOCOCCUS 
  
STAPHYLOCOCCUS AUREUS ( N =31) 
 
 
DRUG 
RESISTANCE 
 
SUSCEPTIBLE 
  
Sl.no No. PERCENTAGE No. PERCENTAGE 
1 Ampicillin 31 100.00 0 0.00 
2 Amoxycillin 31 100.00 0 0.00 
3 Amoxyclav 0 0.00 31 100.00 
4 Oxacillin 8 25.81 23 74.19 
5 Erythromycin 0 0.00 31 100.00 
4 Azithromycin 0 0.00 31 100.00 
7 Cotrimoxazole 0 0.00 31 100.00 
8 Doxycycline 0 0.00 31 100.00 
9 Amikacin 0 0.00 31 100.00 
10 Gentamicin 0 0.00 31 100.00 
11 Ciprofloxacin 0 0.00 31 100.00 
12 Ofloxacin 0 0.00 31 100.00 
13 Cephelexin 0 0.00 31 100.00 
14 Cefixime 31 100.00 0 0.00 
15 Cefotaxime 8 25.81 23 74.19 
16 Ceftrioxone 8 25.81 23 74.19 
17 Ceftazidime 28 90.32 3 9.68 
18 Ceftazidime+clav 31 100.00 0 0.00 
19 Cefipime 5 16.13 26 83.87 
20 Piperacillin+Tazo 0 0.00 31 100.00 
21 Aztreonam 8 25.81 23 74.19 
22 Imipenam 0 0.00 31 100.00 
23 Vancomycin 0 0.00 31 100.00 
 
 MRSA constitutes 26% of the total Staphylococcal  isolates.Multidrug resistance 
was a common feature observed among the organisms. 
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CHART 11: AMS Pattern of STAPHYLOCOCCUS 
 
 
CHART  12 : AMS PATTERN OF PSEUDOMONAS ISOLATES 
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TABLE17:   AMS PATTERN OF PSEUDOMONAS 
PSEUDOMONAS ( N=28) 
 
 
Sl.NO. DRUG 
RESISTANT 
 
SUSCEPTIBLE 
 
No. PERCENTAGE  No. 
 
PERCENTAGE 
1 Ampicillin 28 100 0 0 
2 Amoxycillin 28 100 0 0 
3 Amoxyclav 25 89.28 3 10.71 
4 Oxacillin 0 0 0 0 
5 Erythromycin 0 0 0 0 
4 Azithromycin 6 21.42 22 78.57 
7 Cotrimoxazole 28 100 0  0 
8 Doxycycline 28 100 0  0 
9 Amikacin 3 10.71 25 89.28 
10 Gentamicin 8 28.57 20 71.42 
11 Ciprofloxacin 6 21.42 22 78.57 
12 Ofloxacin 14 50 14 50 
13 Cephelexin 28 100 0 0 
14 Cefixime 28 100 0 0 
15 Cefotaxime 14 50 14 50 
16 Ceftrioxone 14 50 14 50 
17 Ceftazidime 20 71.42 8 28.57 
18 Ceftazidime+clav 6 21.42 22 78.57 
19 Cefipime 20 71.42 8 28.57 
20 Piperacillin+Tazo 0 0 28 100 
21 Aztreonam 11 39.28 17 60.71 
22 Imipenam 0 0 28 100 
23 Vancomycin 0 0 0 0 
 
 All the isolates are resistant to Ampicillin, Amoxycillin, Cotrimoxazole, 
Doxycycline, Cephelexin and Cefixime while all are susceptible to Piperacillin-
Tazobactum and Imipenam. Prevalence of ESBL producers is 21.5%. 
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TABLE18:   AMS PATTERN OF KLEBSIELLA 
  
KLEBSIELLA( N=13) 
 
Sl.NO. DRUG 
RESISTANT 
 
SUSCEPTIBLE 
 
No. PERCENTAGE  
 
 
PERCENTAGE 
1 Ampicillin 13 100.00 0 0.00 
2 Amoxycillin 13 100.00 0 0.00 
3 Amoxyclav 9 69.23 4 30.77 
4 Oxacillin 0 0.00 0 0.00 
5 Erythromycin 0 0.00 0 0.00 
4 Azithromycin 0 0.00 13 100.00 
7 Cotrimoxazole 9 69.23 4 30.77 
8 Doxycycline 4 30.77 9 69.23 
9 Amikacin 0 0.00 13 100.00 
10 Gentamicin 0 0.00 13 100.00 
11 Ciprofloxacin 4 30.77 9 69.23 
12 Ofloxacin 4 30.77 9 69.23 
13 Cephelexin 4 30.77 9 69.23 
14 Cefixime 13 100.00   0.00 
15 Cefotaxime 4 30.77 9 69.23 
16 Ceftrioxone 4 30.77 9 69.23 
17 Ceftazidime 8 61.54 5 38.46 
18 Ceftazidime+clav 4 30.77 9 69.23 
19 Cefipime 4 30.77 9 69.23 
20 Piperacillin+Tazo 0 0.00 13 100.00 
21 Aztreonam 4 30.77 9 69.23 
22 Imipenam   0.00 13 100.00 
23 Vancomycin 0 0.00 0 0.00 
 
All the isolates are resistant to Ampicillin, Amoxycillin and Cefixime while all 
are susceptible to Aminoglycosides, Aithromycin, Piperacillin-Tazobactum, and 
Imipenam. Prevalence of ESBL producers is 31%. 
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CHART 13 :  AMS PATTERN OF KLEBSIELLA ISOLATES 
  
 
 CHART 14: AMS PATTERN OF ENTEROBACTER 
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TABLE19:   AMS PATTERN OF ENTEROBACTER 
  
ENTEROBACTER( N=24) 
 
Sl.NO DRUG 
RESISTANT 
 
SUSCEPTIBLE 
 
No. PERCENTAGE  
 
PERCENTAGE 
 
1 Ampicillin 24 100.00 0 0.00 
2 Amoxycillin 24 100.00 0 0.00 
3 Amoxyclav 24 100.00 0 0.00 
4 Oxacillin 0 0.00 0 0.00 
5 Erythromycin 0 0.00 0 0.00 
4 Azithromycin 12 50.00 12 50.00 
7 Cotrimoxazole 24 100.00 0 0.00 
8 Doxycycline 10 41.67 14 58.33 
9 Amikacin 24 100.00 0 0.00 
10 Gentamicin 12 50.00 12 50.00 
11 Ciprofloxacin 12 50.00 12 50.00 
12 Ofloxacin 22 91.67 2 8.33 
13 Cephelexin 22 91.67 2 8.33 
14 Cefixime 19 79.17 5 20.83 
15 Cefotaxime 12 50.00 12 50.00 
16 Ceftrioxone 14 58.33 10 41.67 
17 Ceftazidime 17 70.83 7 29.17 
18 Ceftazidime+clav 10 41.67 14 58.33 
19 Cefipime 12 50.00 12 50.00 
20 Piperacillin+Tazo 0 0.00 24 100.00 
21 Aztreonam 17 70.83 7 29.17 
22 Imipenam 0 0.00 24 100.00 
23 Vancomycin 0 0.00 0 0.00 
 
All the isolates are resistant to Ampicillin, Amoxycillin, Amoxyclav, 
Cotrimoxazole and Amikacin .All are susceptible to Piperacillin-Tazobactum, and 
Imipenam. Prevalence of ESBL producers is 42%. 
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TABLE 20:   AMS PATTERN OF PROTEUS 
 
PROTEUS N=25 
 
Sl.NO DRUG 
RESISTANT 
 
SUSCEPTIBLE 
 
No. PERCENTAGE  
 
 
PERCENTAGE 
1 Ampicillin 16 64 9 36 
2 Amoxycillin 16 64 9 36 
3 Amoxyclav 12 48 13 52 
4 Oxacillin 0 0 0 0 
5 Erythromycin 0 0 0 0 
4 Azithromycin 3 12 22 88 
7 Cotrimoxazole 16 64 9 36 
8 Doxycycline 3 12 22 88 
9 Amikacin 0 0 25 100 
10 Gentamicin 0 0 25 100 
11 Ciprofloxacin 3 12 22 88 
12 Ofloxacin 3 12 22 88 
13 Cephelexin 6 24 19 76 
14 Cefixime 13 52 12 48 
15 Cefotaxime 3 12 22 88 
16 Ceftrioxone 3 12 22 88 
17 Ceftazidime 3 12 22 88 
18 Ceftazidime+clav 3 12 25 100 
19 Cefipime 3 12 22 88 
20 Piperacillin+Tazo 0 0 25 100 
21 Aztreonam 3 12 22 88 
22 Imipenam 0 0 25 100 
23 Vancomycin 0 0 0 0 
 
 100% sensitivity was observed for Aminoglycosides, Ceftazidime – Clavulanic 
acid, Piperacillin – Tazobactum and Imipenam.64% of the organisms were resistant to 
Ampicillin and Amoxycillin. 
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CHART 15: AMS PATTERN OF PROTEUS 
 
 
CHART 16: AMS PATTERN OF ESCHERICHIA COLI 
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TABLE 21:   AMS PATTERN OF E COLI 
 
E COLI N=10 
Sl.NO DRUG 
RESISTANT 
 
SUSCEPTIBLE 
 
No. PERCENTAGE No. 
 
PERCENTAGE 
 
1 Ampicillin 10 100 0 0 
2 Amoxycillin 10 100 0 0 
3 Amoxyclav 3 30 7 70 
4 Oxacillin 0 0 0 0 
5 Erythromycin 0 0 0 0 
4 Azithromycin 5 50 5 50 
7 Cotrimoxazole 10 100 0 0 
8 Doxycycline 5 50 5 50 
9 Amikacin 5 50 5 50 
10 Gentamicin 2 20 8 80 
11 Ciprofloxacin 8 80 2 20 
12 Ofloxacin 8 80 2 20 
13 Cephelexin 8 80 2 20 
14 Cefixime 8 80 2 20 
15 Cefotaxime 5 50 5 50 
16 Ceftrioxone 8 80 2 20 
17 Ceftazidime 8 80 2 20 
18 Ceftazidime+clav 6 60 4 40 
19 Cefipime 8 80 2 20 
20 Piperacillin+Tazo 0 0 10 100 
21 Aztreonam 5 50 5 50 
22 Imipenam 0 0 10 100 
23 Vancomycin   0   0 
 
 All the isolates are resistant to Ampicillin, Amoxycillin and Cotrimoxazole while 
all are susceptible to Piperacillin-Tazobactum and Imipenam. Prevalence of ESBL 
producers is 60%. 
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DISCUSSION 
As the domestic and international incidence of diabetes and its related 
complications continues to rise, medical fraternity needs to continue to improvise the 
management of the same. Since the burden on socioeconomic aspects is on the ascending 
mode, a like-minded multidisciplinary team approach is needed to optimize the patient 
care. Early recognition of severe infections in addition to other modalities of 
management is a crucial component of managing diabetic foot infections.  
AGE AND SEX WISE DISTRIBUTION: 
 In this study the incidence of the disease is more among men than women as 
supported by various international and national data95. Among the total 142 patients 
59.85% constitutes male population, the remaining 40.15% being the female population. 
 The mean age of the subjects was 56.75years. Older population falling in the age 
group of 60 – 69 years contributes the majority (32%) of the diseased undergoing 
treatment for DFI in our hospital. This may be attributed to lesser survival rate among 
above-70 age group in our country which in turn puts the blame on socioeconomic 
factors.  
DISEASE DURATION: 
 The mean duration of Diabetes was 7.58 years and more than half of the 
population (56%) had the disease for ≥5years.This may be explained by the increasing 
awareness about the illness among people. Prolonged duration of illness and hence long 
periods of hyperglycemia predisposes to MDRO incidence. This is in harmony with the 
Observations by Ravishankar Gadepalli et al in a field study in North India.97,98 
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ASSOCIATED COMPLICATIONS: 
 The incidence of other diabetes related complications in patients presented with 
DFI is as follows – 125 among 142 i.e.88% of the patients presented with Neuropathy. 
Various studies all over the world3, 14,98,99,100,101 including The IDSA guideline   support 
and confirm this finding. Peripheral vascular disease was observed in 89% of the 
patients. Retinopathy – 29(20%), Hypertension - 43(30%). Nephropathy – 40 (28%) 
were the other diabetes related comorbidities observed. There is a positive correlation 
between the incidence of MDRO and peripheral vascular disease which is supported by 
other studies.   
PROFILE OF PATHOGENS IN DFI: 
 Of the 142 cases studied 23 did not yield any pathogen on culture which may be 
attributed to prior antibiotic therapy, organism’s less than critical level colonization or 
unfavourable growth conditions (Anaerobes were not included in this study). 
119 specimens yielded bacterial growth of which 38 showed polymicrobial 
isolates. A total of 165 aerobic bacteria were isolated, 96 (58%) being Gram negative, 69 
(42%) being Gram positive, giving the majority to Gram negative bacilli. This is in 
contrast to Western studies36, 37, 38, and 39 but in concurrence with national scenario40.
  
 Staphylococcus aureus ranks first among the bacterial pathogens amounting to 
26% of the isolates which correlates with national and Global occurrence39, 41, 42. 
Pseudomonas aeruginosa follows with 23.5% of incidence42. Proteus (21%), 
Enterococcus sp (13%), Enterobacter (12%), Klebsiella (11%), CONS & E.coli (8.4%) 
are the other significant isolates that worth mention here. 
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POLYMICROBIAL NATURE: 
 In this study incidence of polymicrobial isolates in chronic DFI is around     27 % 
i.e. from 38 out of 142 samples two to three organisms were isolated. Further it is 
influenced by the duration of illness and hospital stay i.e.36 out of 38 (94.7%) 
polymicrobial growth was observed in subjects with illness for ≥5 years. The inherent 
susceptibility to infection in diabetics attributed to impaired leukocyte chemotaxis and 
phagocytosis is exhibited by this polymicrobial isolation. 37 out of 38 (97.3%) patients 
showing polymicrobial growth stayed in the hospital for ≥4weeks. The contamination 
and colonization by hospital flora is the obvious factor behind hence needs no 
explanation. These findings correlate with South Indian, North Indian and global 
data.97,98  
MULTIDRUG RESISTACE: 
 The MDR isolates among the total isolates constitutes 43% i.e.71 out of 165 
isolates. Patients who stayed in the hospital for ≥ 4weeks harboured 70.4% of the MDR 
isolates. Increasing prevalence of multidrug resistance among hospital flora explains this 
scenario. Patients with prolonged duration of illness showed increased isolation of MDR 
organisms amounting to 80.3% of total MDRO isolated in this study. Molecular level 
insults done by prolonged hyperglycemia compromising the vascularity and hence the 
achievement of therapeutic index of antimicrobials of MDRO in the community itself. 
Retrospective analysis shows MDRO infected patients had poor glycemic control during 
the course of illness. This is in harmony with AIIMS study by Ravisheher et al.Similarly 
coexistent Hypertension also predisposes to MDRO infection. Rational usage of 
antimicrobials based on the local prevalence of organisms and their sensitivity pattern is 
the need of the hour. Further research aimed in this direction to obtain and document the 
local microbial flora and resistance scenario is essential. 
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AMS PATTERN OF STAPHYLOCOCCUS AUREUS: 
 Staphylococcus aureus is the commonest aerobic bacteria isolated in this study. 
This is in harmony with various studies in different localities of the world.96The AMS 
profile of the organism  showed 74% of MSSA  and 26% of MRSA. Irrespective of the 
Methicillin susceptibility status, invariably all the Staphylococcal isolates showed 
resistance to Ampicillin, Amoxycillin, Cefixime and Ceftazidime-Clavulanic acid 
combination. The isolates resistant to Ceftazidime-Clavulanic acid combination are all 
invariably sensitive to Amoxycillin Clavulanic acid combination.This paradoxical 
observation warrants meticulous field studies for its approval or denial. The data is not 
supported by other studies which document a higher prevalence of MRSA. Continued 
surveillance in various departments is needed to evaluate this observation.  
AMS PATTERN OF PSEUDOMONAS ISOLATES 
 Pseudomonas aeruginosa is the next common organism isolated from the  lesions 
in this study constituting 17% of the total isolates. All the isolates are resistant to 
Ampicillin, Amoxycillin, Cotrimoxazole, Doxycycline, Cephelexin and Cefixime while 
all are susceptible to Piperacillin-Tazobactum and Imipenam. Prevalence of ESBL 
producers is 21.5%. There was a higher incidence of Pseudomonas in patients who 
stayed for longer periods in the hospital. Piperacillin-Tazobactum and Imipenam remain 
the choice of antimicrobial for the MDR isolates. 
 Incidence of Enterobacter among the total isolates is 15% which is comparatively 
higher than the earlier studies. A simple motility examination improved the number of 
isolates differentiating from Klebsiella species. ESBL production among the 
Enterobacter isolates is 42% that needs concern. All the isolates are resistant to 
Amikacin. Piperacillin-Tazobactum and Imipenam are the available drugs for 
management. 
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 Uniform resistance of the organisms to Ampicillin, Amoxycillin and Cefixime 
warrants special mention in view of them being the first line drug in almost all the 
Primary Health Centres and over the counter availability for all undiagnosed infections. 
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CONCLUSION 
This study presents a comprehensive clinical and bacteriological survey of 
diabetic foot infection in our locality. The non-availability of local data regarding the 
profile of organisms and their antimicrobial sensitivity pattern is a stimulus for this 
study. 
Though earlier data suggest the Gram Positive aerobic bacteria as predominant 
isolates from infected diabetic foot ulcers, the aerobic Gram negative bacilli are the most 
frequently isolated. Hence the major etiological factors for DFI in our patients are 
different. Isolation of multidrug resistant Pseudomonas aeruginosa and increasing 
fraction of Enterobacter species raises a serious concern about the treatment modality. 
Higher prevalence of both MRSA isolates and ESBL producing Gram negative 
organisms confirms that MDRO infection is alarmingly higher in our patients on 
treatment for diabetic foot infection. The place of study being a referral centre with 
fluent usage of broad spectrum antibiotics and the non compliance of the patients to 
prolonged treatment may be the possibility behind. 
The increased duration of Diabetes per se, prolonged hospital stay, poor glycemic 
control , associated peripheral vascular disease in addition to  neuropathy are identified 
as significant risk factors for MDRO infections in this study that is also supported by 
earlier Indian and global studies as mentioned earlier . The need for surgical management 
is found to be more in these cases. This finding suggests the necessity to develop an 
effective economical empirical antimicrobial policy tailored to the local data obtained 
and discussed here. 
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Trivial measures like earlier assessment of neuropathy, education about foot care 
&foot-wear, awareness about minor infections and foot hygiene ill have major impact in 
the course and management of Diabetic foot infections.  
Apart from derivation of an empirical antimicrobial regimen this study 
emphasizes the necessity for development of DIABETIC FOOT CARE TEAM 
comprising of medical, surgical, paramedical and infectious disease specialists to 
implement the recommended multidisciplinary approach in the management of Diabetic 
foot infection.  
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INFORMED CONSENT 
 
I have been informed about the study of Diabetic Foot Infection.  I 
totally agree to participate in the study, as I realize the importance of the 
study.  I am also aware that I can withdraw from the study whenever I want. 
 
 
Date  :              Signature of the patient 
Department :  
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STUDY ON CLINICOMICROBIOLOGICAL PROFILE OF DIABETIC 
FOOT INFECTIONS 
 
PATIENT PROFORMA 
Name:      Age/Sex:   Ward/Unit: 
OP/IP No.:   CENTRAL LAB No:    MICRO No: 
Type of Diabetes: 
Duration of Diabetes: 
Glycemic control: 
Associated Complications: 
 i) Retinopathy      - 
 ii) Neuropathy      - 
 iii) Nephropathy – 
 iv)  Hypertension – 
 v) Peripheral vascular disease: 
Duration & Size of Ulcer: 
 
Duration of Hospital stay: 
 
Clinical Outcome: 
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WORKSHEET 
 
Specimen   :  Pus, Aspirate  
Method of collection  : Deep swabbing, Aspiration, Curetting 
I. Macroscopic Examination : Consistency, Presence of blood, Colour, Odour 
II. Microscopic Examination : Direct  Gram staining 
III. Culture    :   
Nutrient agar  :      
  MacConkey agar :       
 Blood agar  : 
Gram staining   : 
Motility   : 
IV. Biochemical Reactions: 
Catalase   : 
Oxidase   : 
Sugar fermentation tests : 
IMViC    : 
Urease    : 
TSI    : 
LAO    :    Special Tests: 
Coagulase    : 
Micro organism isolated : 
V. Anti Microbial Susceptibility test :  Antibiogram on MHA by Kirby Bauyer method 
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ANTIBIOGRAM 
S.No 
              DRUG A B C Remarks 
1.  Ampicillin     
2.  Amoxycillin     
3.  Amoxyclav     
4.  Oxacillin     
5.  Erythromycin     
6.  Azithromycin     
7.  Cotimoxazole     
8.  Doxycycline     
9.  Amikacin     
10.  Gentamicin     
11.  Ciprofloxacin     
12.  Ofloxacin     
13.  Cephelexin     
14.  Cefixime     
15.  Cefotaxime     
16.  Ceftrioxone     
17.  Ceftazidime     
18.  Ceftazidime+clav     
19.  Cefipime     
20.  Piperacillin+Tazo     
21.  Aztreonam     
22.  Imipenam     
23.  Vancomycin     
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VI. Screening for MRSA     
MHA with 4%Nacl  : 
 
VII. Conformation of MRSA  :  
 Oxacillin Screen Agar  :          
VIII. Screening for ESBL     
 Double disc synergy test : 
   
IX. Conformation of ESBL :            
1. Double disc potentiation :               
 2. E Test    : 
X.Screening for Amp C β-lactamases:  
1. Cefoxitin resistant strain : 
            2. Double disc antagonism test: 
XI.Confirmation for Amp C β-lactamases:  
Amp C disc test: 
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GRAM STAINING: 
The gram stain was prepared as follows: 
PRIMARY DYE: 
Crystal violet                            - 10g 
Ammonium oxalate                 - 4.25g 
Absolute alcohol                       - 50ml 
Distilled water                        -500ml 
The methyl violet dye was dissolved in 50 ml absolute alcohol and mixed 
thoroughly. Then ammonium oxalate 4.25 g was dissolved in 100 ml of distilled 
water and this mixture was added to the violet stain and finally distilled water was 
added to make 500 ml. The total mixture was filtered before use. 
Gram’s iodine solution consists of the following 
Iodine             - 25g 
KI                  - 50G 
DW               - 500ml 
 Fifty grams of KI was dissolved in 500 ml of water and then 25 grams of iodine 
was added to that. When iodine is dissolved, the solution was made up to 500ml 
with distilled water. 
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Counter stain used in grams stain was dilute carbol fuschin. It consists of the following: 
Basic fuschin         - 5g 
Phenol                   -25g 
Absolute alcohol   -50 ml 
The basic fuschin powder was added to alcohol at intervals until it was dissolved. Then 
phenol too was dissolved in distilled water. Both the solution was mixed in a separate 
container. 
CATALASE TEST: 
Done by both slide & tube methods. 
Tube method: 
A small amount of the culture was picked up from the nutrient agar plate with a clean, 
sterile glass rod and inserted into a tube of 3% hydrogen peroxide; there was no 
effervescence or bubble formation. 
Slide method: 
Pure growth of the organism from the agar was transferred to a clean slide with a sterile 
glass rod. Immediately 2 to 3 drops of 3% hydrogen peroxide was added to the growth, 
observed for the release of the bubbles. 
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MEDIA PREPARATION 
1. Peptone water: 
            Peptone               1 g 
            Sodium chloride   0.5 g 
            Distilled water      100 ml              pH – 7.4 
   Sterilise by autoclaving at 121°C for 15 minutes. 
2. Nutrient broth : 
           Peptone water     100ml 
          Beef extract         1 g 
          Ph                       7.4 
         Sterilise by autoclaving at 121°C for 15 minutes. 
3. Nutrient agar : 
   To the nutrient broth, add required amount of agar. Steam to dissolve agar, 
filter, and adjust ph to 7.4. Sterilise by autoclaving at 121°C for 15 min. 
4. Blood agar : 
    To the 100 ml of nutrient agar, in water bath at 50°C, add 5% (5ml) of   Sheep 
blood. 
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5. Mac Conkey agar 
                 Peptone                         20 g 
                Sodium chloride            5 g 
               Sodium taurocholate     5 g 
              Lactose                          10g 
              Neutral red                    10 ml 
              Agar                              15 g 
             Distilled water               1000 ml 
            Sterilise by autoclaving at 121°C for 15 minutes. 
6.  Mueller Hinton Agar: 
         Beef infusion                  300 g/l 
         Casein acid hydrolysate    17.5 g 
          Starch                               1.5 g 
           Agar                                 17 g 
           Distilled water                  1000 ml  
       Sterilise by autoclaving at 121°C for 15 minutes. 
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